Adjuvant Ipilimumab in Melanoma: Future in Doubt Adjuvant Ipilimumab in Melanoma: Future in Doubt

This hugely expensive regimen has now been eclipsed by the checkpoint inhibitor nivolumab, placing the future of adjuvant ipilimumab under question, argues one expert.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news